ArticleClinical cancer research : an official journal of the American Association for Cancer Research2012
Regulatory T cells move in when gliomas say "I Do".
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.Cancer immunology, immunotherapy : CII · 2016Trial
- Within and beyond the tumor: Mechanisms of glioblastoma-induced immunosuppression.Neuro-oncology advances · 2025Review
- Immune factors and their role in tumor aggressiveness in glioblastoma: Atypical cadherin FAT1 as a promising target for combating immune evasion.Cellular & molecular biology letters · 2025Review
- Necrotic reshaping of the glioma microenvironment drives disease progression.Acta neuropathologica · 2022Review
- Immunotherapy Resistance in Glioblastoma.Frontiers in genetics · 2021Review
- Article
- T-cell Dysfunction in Glioblastoma: Applying a New Framework.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Review
- Immune phenotypes predict survival in patients with glioblastoma multiforme.Journal of hematology & oncology · 2016Article
- Immunological Evasion in Glioblastoma.BioMed research international · 2016Review
- A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.Journal of immunology research · 2014Review
- A road less traveled paved by IDO silencing: Harnessing the antitumor activity of neutrophils.Oncoimmunology · 2013Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
Indoleamine 2,3-dioxygenase (IDO) is an enzyme with known immunosuppressive and tolerogenic effects in cancer. Mounting evidence has associated IDO expression with the induction of regulatory T cells (Treg) and malignant progression. IDO inhibition may therefore provide a promising therapeutic approach for glioblastoma, where the need for novel treatment is great.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.